Overview
Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.
Status:
Completed
Completed
Trial end date:
2008-12-01
2008-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bayer
Criteria
Inclusion Criteria:- Male and/or female (without childbearing potential) white patients
- History of persistent or permanent atrial fibrillation
- 18 to 75 years of age
Exclusion Criteria:
- Patients with high-risk cardiovascular diseases
- Stroke or myocardial infarction
- Relevant pathological changes in the ECG or echocardiography
- Medication affecting ventricular response in Afib